Logo image of KMPH

KEMPHARM INC (KMPH) Stock Price, Quote, News and Overview

NASDAQ:KMPH - Nasdaq - US4884452065 - Common Stock - Currency: USD

5.81  -0.02 (-0.34%)

KMPH Quote, Performance and Key Statistics

KEMPHARM INC

NASDAQ:KMPH (2/28/2023, 8:00:03 PM)

5.81

-0.02 (-0.34%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High6.92
52 Week Low4
Market Cap200.47M
Shares34.50M
Float31.30M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-28 2023-03-28/bmo
IPO04-16 2015-04-16


KMPH short term performance overview.The bars show the price performance of KMPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

KMPH long term performance overview.The bars show the price performance of KMPH in the last 1, 2 and 3 years. 1 year 2 years 3 years 2 4 6 8 10

The current stock price of KMPH is 5.81 USD. In the past month the price increased by 7.79%. In the past year, price increased by 10.46%.

KEMPHARM INC / KMPH Daily stock chart

KMPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.44 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.58 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.78 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About KMPH

Company Profile

KMPH logo image KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 24 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The firm also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.

Company Info

KEMPHARM INC

1180 Celebration Blvd Ste 103

Celebration FLORIDA 34747 US

CEO: Travis C. Mickle

Employees: 24

Company Website: http://www.kempharm.com/

Phone: 13219393416.0

KEMPHARM INC / KMPH FAQ

What is the stock price of KEMPHARM INC today?

The current stock price of KMPH is 5.81 USD. The price decreased by -0.34% in the last trading session.


What is the ticker symbol for KEMPHARM INC stock?

The exchange symbol of KEMPHARM INC is KMPH and it is listed on the Nasdaq exchange.


On which exchange is KMPH stock listed?

KMPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KEMPHARM INC stock?

9 analysts have analysed KMPH and the average price target is 22.78 USD. This implies a price increase of 292.08% is expected in the next year compared to the current price of 5.81. Check the KEMPHARM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KEMPHARM INC worth?

KEMPHARM INC (KMPH) has a market capitalization of 200.47M USD. This makes KMPH a Micro Cap stock.


How many employees does KEMPHARM INC have?

KEMPHARM INC (KMPH) currently has 24 employees.


What are the support and resistance levels for KEMPHARM INC (KMPH) stock?

KEMPHARM INC (KMPH) has a support level at 5.43 and a resistance level at 5.87. Check the full technical report for a detailed analysis of KMPH support and resistance levels.


Is KEMPHARM INC (KMPH) expected to grow?

The Revenue of KEMPHARM INC (KMPH) is expected to decline by -59.96% in the next year. Check the estimates tab for more information on the KMPH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KEMPHARM INC (KMPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KEMPHARM INC (KMPH) stock pay dividends?

KMPH does not pay a dividend.


When does KEMPHARM INC (KMPH) report earnings?

KEMPHARM INC (KMPH) will report earnings on 2023-03-28, before the market open.


What is the Price/Earnings (PE) ratio of KEMPHARM INC (KMPH)?

KEMPHARM INC (KMPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).


KMPH Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to KMPH. When comparing the yearly performance of all stocks, KMPH is one of the better performing stocks in the market, outperforming 90.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KMPH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to KMPH. While KMPH seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KMPH Financial Highlights

Over the last trailing twelve months KMPH reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 64.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%-280%
Sales Q2Q%46.26%
EPS 1Y (TTM)64.83%
Revenue 1Y (TTM)-62.3%

KMPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to KMPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -143.91% and a revenue growth -59.96% for KMPH


Ownership
Inst Owners83.06%
Ins Owners21.5%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.44
Price Target22.78 (292.08%)
EPS Next Y-143.91%
Revenue Next Year-59.96%